Celltrion Healthcare, which is in charge of overseas sales of Celltrion products, has won successive government bids in Asia, including Singapore and Malaysia.
Celltrion Healthcare announced on Dec. 23 that it participated in the government’s bid for the autoimmune disease treatment Remsima (Infliximab) held in Singapore in the third quarter, winning the order for the third consecutive year.
Accordingly, Celltrion Healthcare will exclusively supply Remsima to the Health Cluster, which accounts for 90 percent of the infleximab market, in 2020, following this year.
Celltrion Healthcare also won a bid from the Malaysian government to expand its Remsima market. Until now, Remsima had been selling only in the private insurance market, which accounts for half of the Malaysian market. The successful bid this time, however, will also allow the company to make inroads into the public insurance market.
In particular, Celltrion Healthcare expected that the bidding results will have a positive impact on neighboring Asian countries such as Brunei, saying that winning the bids from Singapore and Malaysia is the result of successful direct sales.
At the same time, Celltrion explained that it succeeded in winning the order by beating its rival products with "Herzuma (Trastuzumab)" in a government bid for breast and stomach cancer treatment in Thailand in October.
The bid is equivalent to 40 percent of Thailand's Trastuzumab market. Through the bidding, Celltrion Healthcare will exclusively supply Herzuma to Thailand's state-run hospitals for one year from March next year.
A Celltrion Healthcare official stressed that winning the bids from the three nations is a significant achievement that has once again demonstrated the company’s global direct selling capabilities.